One treatment with onabotulinumtoxinA relieves symptoms of overactive bladder in patients refractory to one or more oral medications.

Farrelly, Elisabeth; Hamid, Rizwan; Lorenzo-Gomez, Maria-Fernanda; Schulte-Baukloh, Heinrich; Yu, Jun; Patel, Anand; Nelson, Mariana

Farrelly, Elisabeth; Hamid, Rizwan; Lorenzo-Gomez, Maria-Fernanda; Schulte-Baukloh, Heinrich; Yu, Jun; Patel, Anand; Nelson, Mariana.

Affiliation

Farrelly E; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
Hamid R; University College London Hospitals, London, UK.
Lorenzo-Gomez MF; University Hospital of Salamanca, Salamanca, Spain.
Schulte-Baukloh H; Department of Urology, Charité University Hospital, Berlin, Germany.
Yu J; AbbVie Inc., North Chicago, Illinois, USA.
Patel A; AbbVie Inc., Marlow, UK.
Nelson M; AbbVie Inc., Irvine, California, USA.

Neurourol Urodyn ; 42(6): 1203-1213, 2023 08.

Article in En | MEDLINE | ID: mdl-37260130

Subject(s)

Botulinum Toxins, Type A; Urinary Bladder, Overactive; Urinary Incontinence; Humans; Urinary Bladder, Overactive/diagnosis; Botulinum Toxins, Type A/adverse effects; Treatment Outcome; Urinary Incontinence/drug therapy; Urinary Incontinence/chemically induced; Urination; Cholinergic Antagonists/therapeutic use

Key words

botulinum toxin A; incontinence; oral cycling; overactive bladder

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Incontinence / Botulinum Toxins, Type A / Urinary Bladder, Overactive Type of study: Diagnostic_studies / Observational_studies Limits: Humans Language: En Journal: Neurourol Urodyn Year: 2023 Type: Article Affiliation country: Sweden

Fulltext

XML

PubMed Links

Search on Google